Real-world Tolerability of Foslevodopa/Foscarbidopa Subcutaneous Infusion in Parkinson’s Disease: Discontinuation Beyond Titration (S26.006)

Key Points

• This research aims to assess the tolerability and reasons for discontinuation of foslevodopa/foscarbidopa continuous subcutaneous infusion in patients with Parkinson's disease beyond the titration phase.
• Evaluated a real-world cohort of patients with Parkinson's disease (PwP).
• Assessed patient-reported side effects and reasons for discontinuation.
• Focused on experiences beyond the initial titration period.
• Identified common side effects reported by patients during the infusion treatment.
• Highlighted reasons for discontinuation of the treatment among patients.
• Demonstrated the importance of patient feedback in assessing treatment tolerability.